EXAS vs MLYS · rev $2.76B vs $2.17B cap
EXACT Sciences Corporation (EXAS) versus Mineralys Therapeutics, Inc. Common Stock (MLYS) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Mineralys Therapeutics, Inc. Common Stock (MLYS) is a biotechnology company listed on US.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
MLYS does not have a complete income-statement cache yet.
EXAS currently screens at market cap $20.03B. MLYS currently screens at market cap $2.17B.
Not investment advice. Open the EXAS and MLYS stock pages for the full models.
Not investment advice.